{"generic":"Respiratory Syncytial Virus Immune Globulin, Human","drugs":["Respigam","Respiratory Syncytial Virus Immune Globulin, Human"],"mono":{"0":{"id":"923528-s-0","title":"Generic Names","mono":"Respiratory Syncytial Virus Immune Globulin, Human"},"1":{"id":"923528-s-1","title":"Dosing and Indications","sub":{"1":{"id":"923528-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Respiratory syncytial virus immune globulin (Respigam(R)) is no longer available in the United States.<\/li><li><b>Respiratory syncytial virus infection, In children with bronchopulmonary dysplasia or a history of premature birth (35 weeks gestation or less); Prophylaxis:<\/b> 750 mg\/kg IV monthly during RSV season (typically begins November, through April); total of 5 doses<\/li><\/ul>"},"3":{"id":"923528-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Respiratory syncytial virus immune globulin (Respigam(R)) is no longer available in the United States [1].<\/li><li>Respiratory syncytial virus infection, In children with bronchopulmonary dysplasia or a history of premature birth (35 weeks gestation or less); Prophylaxis<\/li><\/ul>"}}},"3":{"id":"923528-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923528-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to Respiratory Syncytial Virus immune globulin or other human immunoglobulin<\/li><li>selective IgA deficiency<\/li><li>infants and children with hemodynamically significant congenital heart disease<\/li><\/ul>"},{"id":"923528-s-3-10","title":"Precautions","mono":"<ul><li>pre-existing renal insufficiency<\/li><li>underlying pulmonary disease or congestive heart failure; sensitivity to fluid volume<\/li><li>clinically apparent fluid overload<\/li><li>monitor patients for fluid overload, especially patients with bronchopulmonary dysplasia<\/li><li>meales-mumps-rubella and varicella vaccines should be deferred for 9 months after the last dose of RSVIG<\/li><\/ul>"},{"id":"923528-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"923528-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"923528-s-4","title":"Drug Interactions","sub":{"2":{"id":"923528-s-4-15","title":"Moderate","mono":"<ul><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"923528-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Gastroenteritis, Vomiting<\/li><li><b>Other:<\/b>Fever<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (1%), Hypotension (rare), Tachyarrhythmia (1%)<\/li><li><b>Endocrine metabolic:<\/b>Hypervolemia (1%)<\/li><li><b>Hematologic:<\/b>Desaturation of blood (1%)<\/li><li><b>Respiratory:<\/b>Respiratory crackles (1%), Respiratory distress, Exacerbation (2%), Tachypnea (1%), Wheezing (2%)<\/li><\/ul>"},"6":{"id":"923528-s-6","title":"Drug Name Info","sub":{"0":{"id":"923528-s-6-17","title":"US Trade Names","mono":"Respigam<br\/>"},"2":{"id":"923528-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"923528-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"923528-s-7","title":"Mechanism Of Action","mono":"Systemic: RSV-IGIV contains a high concentration of neutralizing and protective antibodies directed against RSV .  In vitro  tests demonstrated that RSV-IGIV can neutralize clinical isolates of RSV .<br\/>"},"8":{"id":"923528-s-8","title":"Pharmacokinetics","sub":{"4":{"id":"923528-s-8-27","title":"Elimination Half Life","mono":"Systemic: 22 to 28 d <br\/>"}}},"9":{"id":"923528-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do NOT dilute<\/li><li>initiate infusion at 1.5 mL\/kg\/hr for 15 minutes; if tolerated increase to 3.6 mL\/kg\/hr for remainder of infusion<\/li><li>especially ill children with bronchopulmonary dysplasia may require a slower infusion rate<\/li><\/ul>"},"10":{"id":"923528-s-10","title":"Monitoring","mono":"<ul><li>respiratory status, vital signs<\/li><li>renal function, urine output; baseline and periodically following infusion<\/li><\/ul>"},"13":{"id":"923528-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid having Measles-Mumps-Rubella and Varicella vaccinations for 9 mo after therapy. Healthcare professional should be consulted before other vaccinations are considered.<\/li><li>This drug may cause diarrhea, gastroenteritis, vomiting, and fever.<\/li><li>Patients with bronchopulmonary dysplasia have increased risk of fluid overload while taking drug. Advise patient's caretaker to report wheezing, tachypnea, and respiratory distress.<\/li><li>Advise patient's caretaker to call healthcare professional if a treatment is missed, as drug must be given on a fixed schedule.<\/li><\/ul>"}}}